Published in:
Open Access
01-02-2009 | Original
Remifentanil-propofol analgo-sedation shortens duration of ventilation and length of ICU stay compared to a conventional regimen: a centre randomised, cross-over, open-label study in the Netherlands
Authors:
F. Willem Rozendaal, Peter E. Spronk, Ferdinand F. Snellen, Adri Schoen, Arthur R. H. van Zanten, Norbert A. Foudraine, Paul G. H. Mulder, Jan Bakker, On behalf of the other UltiSAFE investigators
Published in:
Intensive Care Medicine
|
Issue 2/2009
Login to get access
Abstract
Objective
Compare duration of mechanical ventilation (MV), weaning time, ICU-LOS (ICU-LOS), efficacy and safety of remifentanil-based regimen with conventional sedation and analgesia.
Design
Centre randomised, open-label, crossover, ‘real-life’ study.
Setting
15 Dutch hospitals.
Patients
Adult medical and post-surgical ICU patients with anticipated short-term (2–3 days) MV.
Interventions
Patient cohorts were randomised to remifentanil-based regimen (n = 96) with propofol as required, for a maximum of 10 days, or to conventional regimens (n = 109) of propofol, midazolam or lorazepam combined with fentanyl or morphine.
Measurements and main results
Outcomes were weaning time, duration of MV, ICU-LOS, sedation- and analgesia levels, intensivist/ICU nurse satisfaction, adverse events, mean arterial pressure, heart rate. Median duration of ventilation (MV) was 5.1 days with conventional treatment versus 3.9 days with remifentanil (NS). The remifentanil-based regimen reduced median weaning time by 18.9 h (P = 0.0001). Median ICU-LOS was 7.9 days versus 5.9 days, respectively (NS). However, the treatment effects on duration of MV and ICU stay were time-dependent: patients were almost twice as likely to be extubated (P = 0.018) and discharged from the ICU (P = 0.05) on day 1–3. Propofol doses were reduced by 20% (P = 0.05). Remifentanil also improved sedation-agitation scores (P < 0.0001) and intensivist/ICU nurse satisfaction (P < 0.0001). All other outcomes were comparable.
Conclusions
In patients with an expected short-term duration of MV, remifentanil significantly improves sedation and agitation levels and reduces weaning time. This contributes to a shorter duration of MV and ICU-LOS.